Dwarfism

Causes of Dwarfism (Short Stature)

• Short stature, clinically defined as a standing height that is more than 2 standard deviations (SD) below the mean for chronological age and sex, or below the 3rd percentile, is caused by decreased growth plate chondrogenesis.
• The etiologies of short stature can be broadly categorized into primary (intrinsic to the growth plate), secondary (systemic conditions affecting growth), and idiopathic/normal variants.

Primary (Intrinsic Growth Plate) Causes

• Primary growth plate impairment involves abnormalities in paracrine signaling, cartilage matrix, or intracellular factors, often leading to bone malformations known as skeletal dysplasias (chondrodysplasias), or presenting as syndromic short stature.
• Fibroblast Growth Factor Receptor (FGFR3) Defects: Gain-of-function mutations in the FGFR3 gene negatively regulate growth plate chondrogenesis.
• Achondroplasia is the most common chondrodysplasia, usually resulting from a de novo FGFR3 mutation, presenting with rhizomelic (proximal) short limbs, a large head, frontal bossing, midface hypoplasia, and an increased upper-to-lower segment ratio.
• Hypochondroplasia presents with a milder phenotype of rhizomelic short stature, brachydactyly, and limited elbow extension.
• Thanatophoric dysplasia (Types I and II) represents the most severe, lethal form of FGFR3 mutation, characterized by extremely short limbs, malformed skulls (cloverleaf), and respiratory insufficiency.
• SHOX Gene Defects: The Short Stature Homeobox (SHOX) gene, located in the pseudoautosomal region of the X and Y chromosomes, is crucial for growth plate function in the forearms and lower legs.
• SHOX haploinsufficiency causes Leri-Weill dyschondrosteosis, characterized by mesomelic limb shortening, Madelung deformity of the wrist, high-arched palate, and cubitus valgus.
• Loss of one SHOX copy is the primary mechanism for the severe short stature seen in Turner syndrome (45,X).
• Natriuretic Peptide Receptor (NPR2) Defects: C-type natriuretic peptide stimulates chondrogenesis; loss-of-function mutations in its receptor (NPR2) cause acromesomelic dysplasia (Maroteaux type) or isolated short stature with short metacarpals.
• Cartilage Extracellular Matrix Defects: Mutations in genes encoding matrix proteins impair chondrogenesis.
• Aggrecan (ACAN) mutations cause spondyloepimetaphyseal dysplasia or isolated short stature characteristically associated with an advanced bone age and early growth cessation.
• Collagen mutations (COL10A1, COL2A1) cause conditions like metaphyseal chondrodysplasia (Schmid type) or osteogenesis imperfecta.
• Parathyroid Hormone-Related Protein (PTHrP) and Indian Hedgehog (IHH) Defects: Loss-of-function mutations in PTH1R cause Blomstrand lethal chondrodysplasia, while IHH mutations cause brachydactyly type A1 or short stature with nonspecific skeletal abnormalities.
• GNAS mutations cause pseudohypoparathyroidism type 1A (Albright hereditary osteodystrophy), presenting with short stature, round facies, obesity, brachydactyly, and advanced bone age.
• Syndromic and Chromosomal Causes:
• Turner syndrome (45,X or mosaicism) affects females and presents with short stature, webbed neck, cubitus valgus, primary amenorrhea, and gonadal dysgenesis.
• Down syndrome (Trisomy 21) is universally associated with delayed growth and short stature.
• Noonan syndrome, primarily caused by PTPN11 mutations in the RAS-MAPK pathway, presents with short stature, webbed neck, pulmonary stenosis, delayed puberty, and relative thinness.
• Prader-Willi syndrome presents with severe infantile hypotonia, hyperphagia, central obesity, hypogonadism, and short stature related to functional growth hormone deficiency and premature epiphyseal fusion from early adrenarche.
• Silver-Russell syndrome represents an imprinting disorder presenting with severe pre- and postnatal growth restriction, relative macrocephaly, a triangular face, body asymmetry, and feeding difficulties.
• Primordial dwarfisms (e.g., Seckel syndrome, 3-M syndrome, Bloom syndrome) involve defects in fundamental cellular functions like DNA replication or centrosome formation, resulting in extreme intrauterine and extrauterine growth failure and microcephaly.

Secondary (Systemic) Causes

• Secondary growth impairment involves systemic conditions that secondarily affect growth plate chondrocytes through endocrine, nutritional, inflammatory, or metabolic derangements.
• Endocrine Deficiencies:
• Growth Hormone Deficiency (GHD) can be congenital or acquired, isolated or part of multiple pituitary hormone deficiency (MPHD).
• Congenital GHD arises from genetic defects (GH1, GHRHR), transcription factor defects (PROP1, POU1F1, HESX1, LHX3), or developmental anomalies like septo-optic dysplasia, holoprosencephaly, or pituitary aplasia.
• Acquired GHD results from CNS tumors (craniopharyngioma, germinoma), cranial irradiation (often >35 Gy), CNS trauma, histiocytosis, or autoimmune hypophysitis.
• Growth Hormone Insensitivity (Laron syndrome) is an autosomal recessive disorder mostly caused by GHR mutations, presenting with severe short stature, craniofacial disproportion, prominent forehead, midfacial hypoplasia, micropenis, and extremely low IGF-1 despite high basal GH levels.
• Post-receptor GH insensitivity, such as STAT5b mutations, causes growth failure combined with severe immune deficiency and eczema.
• Hypothyroidism (Congenital or Acquired) severely blunts linear growth, delays bone age, and causes prolonged retention of infantile proportions; acquired forms (like Hashimoto thyroiditis) may present solely with growth arrest before other classical signs appear.
• Cushing Syndrome (endogenous or exogenous glucocorticoid excess) profoundly inhibits linear growth while promoting central weight gain; the divergence of height (falling percentiles) and weight (increasing percentiles) is pathognomonic.
• Sex Steroid Excess (precocious puberty or congenital adrenal hyperplasia) initially causes a rapid growth spurt but ultimately results in premature epiphyseal fusion and compromised final adult short stature.
• Nutritional Deficiencies:
• Malnutrition (protein-calorie deficiency) is the most common global cause of growth failure, resulting in a state of functional GH insensitivity (high GH, low IGF-1).
• Malabsorption syndromes, particularly Celiac disease and Cystic fibrosis, can present with isolated growth failure before the onset of frank gastrointestinal symptoms.
• Chronic Systemic Illnesses:
• Chronic Kidney Disease (CKD) and renal tubular acidosis stunt growth through multifactorial mechanisms including metabolic acidosis, anorexia, GH insensitivity, and renal osteodystrophy.
• Chronic Inflammatory Bowel Disease (Crohn disease) stunts growth via the direct suppressive effects of pro-inflammatory cytokines (TNF-alpha, IL-6) on the growth plate, combined with malabsorption and glucocorticoid therapy.
• Congenital Heart Disease (cyanotic and acyanotic) impairs growth due to chronic hypoxia and increased metabolic demand paired with anorexia.
• Psychosocial Deprivation:
• Severe emotional and sensory neglect can lead to functional suppression of the GH axis, mimicking true GHD, which reversibly normalizes upon placement in a nurturing environment.

Idiopathic and Normal Variants

• Constitutional Delay of Growth and Puberty (CDGP):
• This is the most common cause of delayed puberty and short stature in adolescent males, characterized by a temporarily slow growth rate, delayed bone age, and a delayed pubertal growth spurt.
• Final adult height is usually preserved and matches the genetic target height.
• Familial (Polygenic) Short Stature:
• Children inherit multiple common genetic variants, each exerting a small negative effect on height, resulting in a stature that is short relative to the general population but appropriate for their mid-parental target height.
• Bone age is typically congruent with chronological age.
• Idiopathic Short Stature (ISS):
• Defined as a height below -2.25 SD without an identifiable nutritional, systemic, endocrine, or monogenic etiology; this remains a diagnosis of exclusion.
• Small for Gestational Age (SGA) with Failure of Catch-up Growth:
• About 10% of infants born SGA fail to achieve spontaneous catch-up growth by 2 years of age, resulting in permanent short stature due to unidentified intrinsic fetal growth restrictions.

Diagnostic Approach and Investigations

Detailed History Taking

• Perinatal and Birth History: Elicit the birth weight and length to determine if the child was Small for Gestational Age (SGA) or intrauterine growth restricted (IUGR).
• Inquire about perinatal insults: Breech delivery, birth asphyxia, recurrent neonatal hypoglycemia, prolonged conjugated jaundice, and microphallus strongly suggest congenital hypopituitarism or isolated GHD.
• Growth Trajectory (Time Course): Analyzing previous growth records is the single most crucial step; plotting on standardized charts reveals whether the growth failure is of prenatal onset (SGA without catch-up) or postnatal onset.
• A deceleration crossing two major percentile lines after age 2 indicates an acquired pathology (e.g., acquired hypothyroidism, brain tumor, IBD).
• Nutritional and Dietary History: Assess caloric intake, meal structures, and potential eating disorders to rule out nutritional stunting; a 3-day diet diary may be required.
• Systemic Review: Elicit symptoms of occult chronic disease: chronic diarrhea, abdominal pain, or blood in stool (Crohn/Celiac); polyuria and polydipsia (Diabetes Insipidus or Chronic Kidney Disease); lethargy, constipation, and cold intolerance (Hypothyroidism); headache, visual field defects, or vomiting (CNS tumors like craniopharyngioma).
• Medication History: Document exogenous use of glucocorticoids (e.g., asthma inhalers, topical steroids, or systemic therapy), stimulants, or antiepileptics which can suppress linear growth.
• Family History: Obtain accurate heights of the mother and father to calculate the Mid-Parental Target Height, identifying if the child's height is appropriate for their genetic background.
• Ask about the pubertal timing of the parents (e.g., age of menarche in mother, continued growth in college for father) to suggest Constitutional Delay of Growth and Puberty (CDGP).
• Construct a pedigree to identify autosomal dominant (e.g., SHOX mutations), autosomal recessive (e.g., Laron syndrome), or X-linked patterns of short stature.

Comprehensive Physical Examination

• Anthropometry: Accurately measure standing height (using a stadiometer), weight, and head circumference, and plot them on appropriate charts.
• Assess Body Mass Index (BMI): A low BMI points to malnutrition, celiac disease, or chronic inflammation. Conversely, a normal-to-high BMI coupled with short stature strongly suggests endocrine etiologies (Hypothyroidism, Cushing syndrome, or GHD).
• Body Proportions: Calculate the Upper-to-Lower Segment (US:LS) ratio and arm span to standing height ratio to distinguish proportionate from disproportionate short stature.
• An increased US:LS ratio (short limbs) suggests Achondroplasia or Hypochondroplasia.
• A decreased US:LS ratio (short trunk) indicates spinal involvement like Morquio syndrome or spondyloepiphyseal dysplasia.
• An increased sitting height index can screen for subtle disproportion seen in SHOX deficiency or NPR2 mutations.
• Dysmorphic Assessment: Inspect for specific phenotypic features of genetic syndromes.
• Turner Syndrome: Webbed neck, low posterior hairline, cubitus valgus, widely spaced nipples, multiple nevi.
• Prader-Willi Syndrome: Almond-shaped eyes, acromicria (small hands/feet), central obesity, severe hypotonia in infancy.
• GHD / Hypopituitarism: Midface hypoplasia, depressed nasal bridge, cherubic immature facies, truncal adiposity, micropenis.
• Silver-Russell Syndrome: Triangular face, prominent forehead, fifth finger clinodactyly, body asymmetry.
• Systemic and Endocrine Signs:
• Examine for goiter, dry/sallow skin, and delayed dentition (Hypothyroidism).
• Check for buffalo hump, central obesity, purplish striae, and hypertension (Cushing syndrome).
• Examine optic fundi for papilledema, and test visual fields by confrontation (craniopharyngioma).
• Assess Sexual Maturity Rating (Tanner staging) to determine if short stature is related to delayed puberty or early epiphyseal fusion from precocious puberty.

Step 1: Baseline Screening and Bone Age

• Bone Age Estimation: Radiograph of the left hand and wrist (Greulich and Pyle Atlas) is mandatory to assess skeletal maturation and remaining growth potential.
• A significantly delayed bone age (>2 years behind chronological age) suggests CDGP, GHD, hypothyroidism, or chronic illness.
• A normal bone age indicates familial short stature.
• An advanced bone age in a short child is highly suggestive of precocious puberty, CAH, ACAN mutations, or pseudohypoparathyroidism.
• General Laboratory Panel: Used to exclude subclinical systemic diseases.
• Complete Blood Count (CBC) and Erythrocyte Sedimentation Rate (ESR) or C-Reactive Protein (CRP) to screen for anemia and inflammatory bowel disease.
• Serum electrolytes, urea, creatinine, and venous blood gas to exclude chronic kidney disease and renal tubular acidosis.
• Liver function tests (ALT, AST, Albumin).
• Calcium, phosphorus, and alkaline phosphatase to rule out rickets/osteodystrophy.
• Tissue transglutaminase IgA (with total IgA) to screen for Celiac disease.
• Urinalysis (to rule out renal disease/proteinuria).

Step 2: Endocrine Evaluation

• Thyroid Function: Serum Free T4 and TSH must be measured to rule out primary (high TSH) and central (low/normal TSH with low Free T4) hypothyroidism.
• GH-IGF Axis Screening:
• Random GH levels are pulsatile and diagnostically useless except in the neonatal period.
• Measure serum IGF-1 and IGF Binding Protein-3 (IGFBP-3), interpreting them against strict age- and pubertal stage-matched normative data.
• Very low IGF-1 and IGFBP-3 strongly suggest GHD, severe malnutrition, or GH insensitivity (Laron syndrome).
• Provocative GH Stimulation Testing:
• Indicated if the clinical picture, severe height deficit (< -3 SD), plummeting growth velocity, or low IGF-1 points to GHD.
• Since false positives are extremely common, two separate provocative tests (using agents like Insulin, Glucagon, Arginine, Clonidine, or Levodopa) must be performed.
• A peak GH response of less than 10 ng/mL (or <7 ng/mL in some specific assays) on both tests confirms the diagnosis of GH deficiency.
• In peripubertal children, sex-steroid priming (with estrogen or testosterone) prior to the test may be required to prevent false-positive failure due to delayed puberty.
• IGF-1 Generation Test: If basal GH is high but IGF-1 is extremely low, this test involves administering recombinant GH for several days and measuring the IGF-1 response to distinguish between GHD and GH insensitivity (Laron syndrome).
• Adrenal Axis: If Cushing syndrome is suspected due to weight gain and growth arrest, perform a 24-hour urinary free cortisol, late-night salivary cortisol, or overnight 1-mg dexamethasone suppression test.

Step 3: Genetic and Specialized Testing

• Karyotype / Chromosomal Microarray:
• A karyotype (analyzing for 45,X or mosaicism) is absolutely mandatory for all females presenting with unexplained short stature, even in the absence of classic dysmorphic features of Turner syndrome.
• In males with short stature and associated genital abnormalities (micropenis, cryptorchidism), karyotyping is also warranted.
• Chromosomal Microarray (CMA) or SNP-array is indicated to identify submicroscopic copy number variations in syndromic children with developmental delay, intellectual disability, or multiple congenital anomalies.
• Next-Generation Sequencing (Targeted Panels or WES):
• When a specific monogenic cause is highly suspected (e.g., disproportionate short stature indicating a skeletal dysplasia), targeted single-gene testing (e.g., FGFR3 for achondroplasia, SHOX for Leri-Weill dyschondrosteosis) is performed.
• Whole Exome Sequencing (WES) or targeted growth-failure gene panels should be considered in severe isolated short stature (Height < -3 SD) or unclassified syndromic presentations to identify mutations in genes like ACAN, NPR2, IHH, or STAT5b.

Step 4: Advanced Imaging

• Magnetic Resonance Imaging (MRI) of the Brain and Pituitary:
• An MRI (with and without contrast) is mandatory for any child diagnosed with central GHD or combined pituitary hormone deficiency to rule out congenital structural defects (ectopic posterior pituitary, hypoplastic anterior pituitary, interrupted stalk, septo-optic dysplasia) and neoplastic space-occupying lesions (craniopharyngioma, germinoma, pituitary adenoma).
• Also indicated in girls with early rapid-onset precocious puberty combined with short stature.
• Skeletal Survey:
• A complete skeletal radiographic survey is required if the physical examination or sitting-height parameters suggest disproportionate short stature, aiding in the classification of specific skeletal dysplasias (e.g., evaluating metaphyseal flaring, epiphyseal stippling, or spinal anomalies).
• Pelvic/Renal Ultrasonography:
• May be utilized in girls to assess internal genitalia, especially if Turner syndrome or precocious puberty is considered, or to evaluate for occult renal anomalies associated with genetic syndromes.